U.S.S.N. 09/715,965 Filed: November 17, 2000 Amendment

porty

6. (amended) The method of claim 1 wherein at the time the enzyme is administered the individual has cancer as evidenced by palpable tumors.

Please add new claims 19-25.

- 19. The method of claim 7 wherein the dosage is in the range of 0.1 to 250 IU chondroitinase AC/tumor for tumors in the size range from 20 mm³ to 15 cm³.
- 20. The method of claim 1 wherein the enzyme is administered in combination with another active agent selected from the group consisting of antibiotics, cytokines, cytotoxic agents, and anti-inflammatories.
- 21. The method of claim 7 wherein the enzyme is administered after excision of the tumor.



- 22. The method of claim 9 wherein the enzyme is administered by a route selected from the group consisting of intravenous, intra-cranial, and depo.
- 23. The method of claim 9 wherein the enzyme is administered using an infusion pump.
 - 24. The method of claim 1 wherein the enzyme is chondroitinase B.
 - 25. The method of claim 8 wherein the enzyme is chondroitinase B.

Remarks

Amendments to Claims and New Claims

Claim 1 has been amended to refer to inhibition of angiogenesis, rather than be specific to treatment of tumors, as originally filed, although applicants maintain their election of treatment